Director — Geno J. Germano: The filing discloses the appointment of a new independent director to fill a newly created board seat, which is a routine governance action rather than an executive departure.

Results of Operations and Financial Condition. On August 11, 2026, Eloxx Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2026 and providing a business update. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including the information contained in the press release fu…

Material Modification to Rights of Security Holders. To the extent required by

Director — Stephen W. Webster: The filing discloses the appointment of new independent directors to fill board vacancies, which is a standard governance action rather than an executive departure.

Unregistered Sales of Equity Securities. On August 20, 2025, the Company entered into that certain Securities Purchase Agreement with the investors party thereto (as amended, the “Purchase Agreement”), pursuant to which the Company issued and sold prefunded warrants to purchase an aggregate of 54,076,677 shares of common stock, par value $0.01 per share (the “Common Stock”), with an exercise price of $0.01 per share. On April 27, 2026, certain of the investors exercised pre-funded warrants to…

Director — Lindsay Androski: The filing discloses the resignation of a director, which is a genuine departure from the board but typically carries lower materiality than the departure of a C-suite executive.

CEO — Sumit Aggarwal: The filing discloses a stock option repricing and vesting acceleration for the CEO, which is a compensatory arrangement rather than a change in management personnel.

Entry into a Material Definitive Agreement. Sixth Amendment to Hercules Loan and Security Agreement On July 10, 2024 (the “Closing Date”), Eloxx Pharmaceuticals, Inc. (the “Company”) entered into the Sixth Amendment (the “Sixth Amendment”) to the Loan and Security Agreement, dated as of September 30, 2021, by and among (i) Hercules Capital, Inc., a Maryland corporation (“Hercules”), in its capacity as administrative agent, and collateral agent, (ii) Hercules Capital IV, L.P., as a lender, (ii…

by reference. Forward-Looking Statements This Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this Form 8-K, including without limitation, statements regarding the Company’s expected performance under the terms of the Amended Loan Agreement and the Royalty Agreement, the anticipated benefits of the Royalty Agreement, and expectations about the achievem…

CEO — Sumit Aggarwal: The filing discloses a stock option repricing for the CEO, which is a compensatory arrangement rather than a change in management personnel.

Entry into a Material Definitive Agreement. On March 11, 2024, Eloxx Pharmaceuticals, Inc. (the “Company” or “Eloxx”) entered into an exclusive license agreement with Almirall, S.A. (“Almirall”) covering the Company’s asset ZKN-013 (the “License Agreement”). Under the terms of the License Agreement, Almirall obtained global rights to develop and commercialize ZKN-013 for the potential treatment of rare dermatological and other diseases associated with nonsense mutations. ZKN-013 is a Phase I…

in its entirety. The sales of the Shares, the Warrants and the shares of Common Stock issuable upon exercise of the Warrants have not been registered under the Securities Act or any state securities laws, and the Shares, the Warrants and the shares of Common Stock issuable upon exercise of the Warrants may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from the registration requirements. The sale of such securities does not involve a pu…

Entry into a Material Definitive Agreement. Fifth Amendment to Hercules Loan and Security Agreement On January 9, 2024 (the “Closing Date”), Eloxx Pharmaceuticals, Inc. (the “Company”) entered into the Fifth Amendment to the Loan and Security Agreement (the “Fifth Amendment”) by and among (i) Hercules Capital, Inc., a Maryland corporation (“Hercules”), in its capacity as administrative agent, and collateral agent, (ii) Hercules Capital IV, L.P., (collectively referred to as the “Lenders”), as…

Chairman of the Board — Tomer Kariv: The Chairman of the Board resigned, which is a significant governance change, but the filing notes no disagreement with the company, suggesting an orderly exit rather than a crisis.

Other Events. On December 15, 2023, Eloxx Pharmaceuticals, Inc. (the “Company”) entered into the Fourth Amendment to the Loan and Security Agreement (the “ Fourth Amendment”) by and among (i) Hercules Capital, Inc., a Maryland corporation (“Hercules”), in its capacity as administrative agent, collateral agent, and a lender, (ii) Hercules Capital IV, L.P., (together with Hercules, the “Lenders”), as a lender, (iii) the Company, as a borrower, (iv) Zikani Therapeutics, Inc., a Delaware corporat…

by reference. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 15, 2023 ELOXX PHARMACEUTICALS, INC. By: /s/ Sumit Aggarwal Name: Sumit Aggarwal Title: President and Chief Executive Officer

Results of Operations and Financial Condition. On November 13, 2023, Eloxx Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the third fiscal quarter ended September 30, 2023 and providing a business update. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including the information contained in the pre…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On October 12, 2023, Eloxx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), received a determination letter (the “Delisting Notification”) from the staff (the “Staff”) of the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that Nasdaq will suspend trading in the Company’s common stock, par value $0.01 per share (the “Common Stock”), effective a…

Entry into a Material Definitive Agreement. On September 18, 2023, Eloxx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with a certain institutional investor (the “Purchaser”). The Purchase Agreement provided for the sale and issuance by the Company of an aggregate of: (i) 305,590 shares (the “Shares”) of the Company’s common stock, $0.01 par value (the “Common Stock”), (ii) a pre-funded warrant (the “Pre-…

in its entirety. The sales of the Private Warrant, the Wainwright Warrants and the shares of Common Stock issuable upon exercise of the Private Warrant and Wainwright Warrants have not been registered under the Securities Act or any state securities laws and the Private Warrant, the Wainwright Warrants and the shares of Common Stock issuable upon exercise of the Private Warrant and the Wainwright Warrants may not be offered or sold in the United States absent registration with the Securities…

Other Events Eloxx Pharmaceuticals, Inc. (the “Company”) is providing the following business update. Recent Developments On September 18, 2023, the Company reported an independent qualitative evaluation by a board-certified anatomic pathologist with diagnostic expertise in medical kidney biopsies of transmission electron microscopy (“TEM”) kidney biopsy results from the Company’s proof-of-concept Phase 2 open-label clinical trial of ELX-02 for the potential treatment of Alport syndrome with n…

Head of Research and Development — Dr. Vijay Modur: The Head of R&D resigned, representing a loss of a key senior executive in a critical function for a pharmaceutical company.

Other Events Eloxx Pharmaceuticals, Inc. (the “Company”) is providing the following business update. Recent Developments On September 7, 2023, Eloxx announced that it has submitted an IND application with the U.S. FDA for ELX-02 for the treatment of Alport syndrome with nonsense mutations. Eloxx also announced that the 3 month post treatment results from its proof-of-concept Phase 2 open-label clinical trial for ELX-02. The increase in UPCR following withdrawal of therapy confirms likely on-t…

CEO — Sumit Aggarwal: The filing describes the approval and grant of equity-based retention awards to the CEO and other employees, which is a compensatory arrangement rather than a change in management personnel.

Results of Operations and Financial Condition. On August 14, 2023, Eloxx Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the second fiscal quarter ended June 30, 2023 and providing a business update. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including the information contained in the press rel…